|
1
|
Garcia-Manero G, Faderl S, O'Brien S,
Cortes J, Talpaz M and Kantarjian HM: Chronic myelogenous leukemia:
A review and update of therapeutic strategies. Cancer. 98:437–57.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kantarjian HM, Giles FJ, O'Brien SM and
Talpaz M: Clinical course and therapy of chronic myelogenous
leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin
North Am. 12:31–80. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nowell PC: Discovery of the Philadelphia
chromosome: A personal perspective. J Clin Invest. 117:2033–2035.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
De Bono JS and Ashworth A: Translating
cancer research into targeted therapeutics. Nature. 467:543–549.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yogalingam G and Pendergast AM: Abl
kinases regulate autophagy by promoting the trafficking and
function of lysosomal components. J Biol Chem. 283:35941–35953.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Daniel L, Ahmed CM, Bloodgood RS, Kidd JR,
Castiglione CM, Duttagupta S and Lebowitz P: Polymorphism of the
human c-abl gene: Relation to incidence and course of chronic
myelogenous leukemia. Oncogene. 1:193–200. 1987.PubMed/NCBI
|
|
7
|
Anand M, Chodda SK, Parikh PM and Nadkarni
JS: Abnormal levels of proinflammatory cytokines in serum and
monocyte cultures from patients with chronic myeloid leukemia in
different stages, and their role in prognosis. Hematol Oncol.
16:143–154. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Singer MK, Assem M, Abdel Ghaffar AB and
Morcos NY: Cytokine profiling as a prognostic markers in chronic
myeloid leukemia patients. Egyp J Immunol. 18:37–46. 2011.
|
|
9
|
Li L, Xu N, Zhang JF, Xu LL, Zhou X, Huang
BT, Li YL and Liu XL: Ephb4/ephrinb2 contributes to imatinib
resistance in chronic myeloid leukemia involved in cytoskeletal
proteins. Int J Med Sci. 13:365–373. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tefferi A, Thiele J, Vannucchi AM and
Barbui T: An overview on CALR and CSF3R mutations and a proposal
for revision of WHO diagnostic criteria for myeloproliferative
neoplasms. Leukemia. 28:1407–1413. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Perez CA, Velez M, Raez LE and Santos ES:
Overcoming the resistance to crizotinib in patients with non-small
cell lung cancer harboring EML4/ALK translocation. Lung Cancer.
84:110–115. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McCubrey JA, Steelman LS, Bertrand FE,
Davis NM, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F,
Maestro R, et al: Multifaceted roles of GSK-3 and Wnt/β-catenin in
hematopoiesis and leukemogenesis: Opportunities for therapeutic
intervention. Leukemia. 28:15–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ouerhani S, Gharbi H, Menif S, Safra I,
Douzi K and Abbes S: KIT mutation detection in Tunisian patients
with newly diagnosed myelogenous leukemia: Prevalence and
prognostic significance. Cancer Genet. 205:436–41. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hoermann G, Greiner G and Valent P:
Cytokine regulation of microenvironmental cells in
myeloproliferative neoplasms. Mediators Inflamm. 2015:8692422015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nikitin A, Egorov S, Daraselia N and Mazo
I: Pathway studio-the analysis and navigation of molecular
networks. Bioinformatics. 19:2155–2157. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Abdelmoez A, Coraça-Huber DC, Thurner GC,
Debbage P, Lukas P, Skvortsov S and Skvortsova II: Screening and
identification of molecular targets for cancer therapy. Cancer
Lett. 387:3–9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li J, Sheng N, Cui R, Feng Y, Shao B, Guo
X, Zhang H and Dai J: Gestational and lactational exposure to
bisphenol AF in maternal rats increases testosterone levels in
23-day-old male offspring. Chemosphere. 163:552–561. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao H, Duan J, Lin D, Shugart YY, Calhoun
V and Wang YP: Sparse representation based biomarker selection for
schizophrenia with integrated analysis of fMRI and SNPs. Neuroimage
102 Pt. 1:220–228. 2014. View Article : Google Scholar
|
|
19
|
Daraselia N, Yuryev A, Egorov S,
Novichkova S, Nikitin A and Mazo I: Extracting human protein
interactions from MEDLINE using a full-sentence parser.
Bioinformatics. 20:604–611. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lorenzi PL, Claerhout S, Mills GB and
Weinstein JN: A curated census of autophagy-modulating proteins and
small molecules: Candidate targets for cancer therapy. Autophagy.
10:1316–1326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sivachenko AY, Yuryev A, Daraselia N and
Mazo I: Molecular networks in microarray analysis. J Bioinform
Comput Biol. 5:429–456. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate: A practical and powerful approach to
multiple testing. J Royal Statistical Society, Series B
(Methodological). 57:289–300. 1995.
|
|
23
|
Opsahl T, Agneessens F and Skvoretz J:
Node centrality in weighted networks: Generalizing degree and
shortest paths. Social Networks. 32:245–251. 2010. View Article : Google Scholar
|
|
24
|
Freeman LC: Centrality in social networks:
Conceptual clarification. Social Networks. 1:215–239. 1978.
View Article : Google Scholar
|
|
25
|
Yang S and Knoke D: Optimal connections:
Strength and distance in valued graphs. Social Networks.
23:285–295. 2001. View Article : Google Scholar
|
|
26
|
Wang J, Cao H, Liao Y, Liu W, Tan L, Tang
Y, Chen J, Xu X, Li H, Luo C, et al: Three dysconnectivity patterns
in treatment-resistant schizophrenia patients and their unaffected
siblings. Neuroimage Clin. 8:95–103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hehlmann R, Hochhaus A and Baccarani M:
European Leukemia Net: Chronic myeloid leukaemia. Lancet.
370:342–350. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gong IY and Kim RB: Impact of genetic
variation in OATP transporters to drug disposition and response.
Drug Metab Pharmacokinet. 28:4–18. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sawyers CL, McLaughlin J and Witte ON:
Genetic requirement for Ras in the transformation of fibroblasts
and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med.
181:307–313. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rahmani M, Nguyen TK, Dent P and Grant S:
The multikinase inhibitor sorafenib induces apoptosis in highly
imatinib mesylate-resistant BCR/ABL+ human leukemia cells in
association with STAT5 inhibition and MCL-1 down-regulation. Mol
Pharmacol. 72:788–795. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bi S, Barton CM, Lemoine NR, Cross NC and
Goldman JM: Retroviral transduction of Philadelphia-positive
chronic myeloid leukemia cells with a human mutant p53 cDNA and its
effect on in vitro proliferation. Exp Hematol. 22:95–99.
1994.PubMed/NCBI
|
|
32
|
Clark RE: Immunotherapeutic strategies in
chronic myeloid leukemia. Curr Hematol Malig Rep. 2:89–94. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pendergast AM, Gishizky ML, Havlik MH and
Witte ON: SH1 domain autophosphorylation of P210 BCR/ABL is
required for transformation but not growth factor independence. Mol
Cell Biol. 13:1728–1736. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lugo TG, Pendergast AM, Muller AJ and
Witte ON: Tyrosine kinase activity and transformation potency of
bcr-abl oncogene products. Science. 247:1079–1082. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Waight JD, Banik D, Griffiths EA, Nemeth
MJ and Abrams SI: Regulation of the interferon regulatory factor-8
(IRF-8) tumor suppressor gene by the signal transducer and
activator of transcription 5 (STAT5) transcription factor in
chronic myeloid leukemia. J Biol Chem. 289:15642–15652. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rossi DJ, Jamieson CH and Weissman IL:
Stems cells and the pathways to aging and cancer. Cell.
132:681–696. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pawarode A, Sait SN, Nganga A, Coignet LJ,
Barcos M and Baer MR: Acute myeloid leukemia developing during
imatinib mesylate therapy for chronic myeloid leukemia in the
absence of new cytogenetic abnormalities. Leuk Res. 31:1589–1592.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kovitz C, Kantarjian H, Garcia-Manero G,
Abruzzo LV and Cortes J: Myelodysplastic syndromes and acute
leukemia developing after imatinib mesylate therapy for chronic
myeloid leukemia. Blood. 108:2811–2813. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Găman AM, Dobrea C and Rotaru I: A case of
non-Hodgkin lymphoma in a patient with chronic myeloid leukemia.
Rom J Morphol Embryol. 54:1141–1145. 2013.PubMed/NCBI
|
